Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

1.379 -0.051 (-3.58%)
Streaming Delayed Price Updated: 10:17 AM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amarin Corp ADR

< Previous 1 2 Next >
Looking Into Amarin Corp's Return On Capital Employed
Amarin Corp (NASDAQ:AMRN) brought in sales totaling $94.63 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 314.74%, resulting in a loss of $31.56 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down; Jobs Report In Focus
Pre-open movers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Upgrades 
Via Benzinga
Recap: Amarin Corp Q1 Earnings
Amarin Corp (NASDAQ:AMRN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Needham cut Cirrus Logic, Inc. (NASDAQ: CRUS) price target from $110 to $100. Cirrus Logic shares rose 4.5% to close at $82.81 on Wednesday. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision. 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Amarin Corp's Earnings: A Preview
Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Amarin Corp... 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
Lower Vascepa Volume Hits Amarin's Q4 Topline Growth
Amarin Corp plc's (NASDAQ: AMRN) Q4 FY21 sales decreased 13.6% Y/Y to $144.49 million, beating the consensus of $141.75 million. The decline was driven primarily by... 
Via Benzinga
Amarin: Q4 Earnings Insights
Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients... 
Via Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're starting off the day right with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Why Amarin Stock Tumbled in November
The biopharma's stock could be near a bottom after last month's double-digit decline. 
Via The Motley Fool
Why Amarin Stock Crushed the Market on Tuesday
An activist investor revealed that it held a small stake in the company. 
Via The Motley Fool
Amarin Posts Encouraging Vascepa Data In Patients With Peripheral Artery Disease
Amarin Corporation plc (NASDAQ: AMRN) reported new data for Vascepa/Vazkepa (icosapent ethyl) at the American Heart Association (AHA) Scientific Sessions. The... 
Via Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
Amarin (AMRN) Q3 2021 Earnings Call Transcript
AMRN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.